Background {#Sec1}
==========

Tumor microenvironment (TME) linked closely with the initiation, promotion, and progression of cancer \[[@CR1]\]. Innate and adaptive immunocytes such as mast cells, macrophages and memory T lymphocytes etc. are the vital components of TME \[[@CR2]\]. Multitudinous studies have demonstrated that these immune cells were significantly associated with survival in solid tumors \[[@CR3], [@CR4]\]. However, it is essential to distinguish among different types of immune cells as they may play differential roles in the TME. Eosinophils, as the important component of innate immune cells, have proven to play significant roles in a multitude of solid tumors.

Eosinophils are granulocytic leukocytes that are associated with multitudinous pathologic conditions including allergic reactions, parasitic and bacterial infections etc. \[[@CR5]\] These cells secrete massive proteins and cytokines upon activation and are involved in a variety of other functions including inducing tissue remodeling and promoting antigen presentation \[[@CR6]\]. In the last decade, activated eosinophils have been deemed to affect carcinogenesis and tumor progression via various mechanisms including modulating innate and adaptive immune responses in TME \[[@CR7]\]. Eosinophils infiltrating into tumor is also called tumor-associated tissue eosinophilia (TATE) \[[@CR8]\]. Recent researches have investigated the TATE in tumor progression and survival, but their results were inconsistent even contradictory \[[@CR9]\]. Hence, it needs further evaluation. In addition, the potential of TATE as prognostic biomarker and therapeutic strategy is also required to be investigated.

Herein, we carried out this meta-analysis to expound the relation between TATE and clinical outcomes including overall survival (OS) and disease-free survival (DFS) in patients with cancer.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

This meta-analysis was guided by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) Statement issued in 2009 (Checklist S1). PubMed, Embase and EBSCO were searched for researches from 1980 to May 15th 2019. The keywords applied for search were: (eosinophil \[Title/Abstract\] OR eosinophilia \[Title/Abstract\]) AND (neoplasms \[Title/Abstract\] OR tumor \[Title/Abstract\] OR cancer \[Title/Abstract\] OR carcinoma \[Title/Abstract\]).

Inclusion and exclusion criteria {#Sec4}
--------------------------------

Researches included in this meta-analysis should meet the following inclusion criteria: (1) been published as original articles; (2) investigated human subjects; (3) examined eosinophils in primary tumor tissues; (4) reported hazard ratios (HRs) with 95% confidence interval (CI), or Kaplan -- Meier curves of eosinophil infiltration with clinical outcomes.

The exclusion criteria were as follows: researches (1) were not published as research articles or full texts including commentaries, case reports, letters to the editors and meeting abstracts; (2) didn't offer ample data to obtain HRs; (3) investigated eosinophils in metastases or not in tumor tissues.

Endpoints {#Sec5}
---------

In this study, OS and DFS were regarded as the primary and second endpoint respectively.

Data extraction {#Sec6}
---------------

GM.H. and SM.W. reviewed and recorded data including number of patients, method to quantify eosinophils, cutoff value to determine TATE and time of follow-up etc. independently. OS, DFS and clinicopathological features such as tumor, node, metastasis (TNM) stage and lymphatic invasion were extracted from the text, tables, or Kaplan -- Meier curves.

Quality assessment {#Sec7}
------------------

Two authors independently assessed the quality of included cohort researches with Newcastle--Ottawa Scale (NOS), \[[@CR10]\] and achieved consensus for each item under the help of third or more authors. Research scored 6 or above was regarded as high quality.

Statistical analysis {#Sec8}
--------------------

We combined extracted data using STATA 12.0 analysis software, and estimated statistical heterogeneity with the chi-squared based Q-test or *I*^*2*^ (25% was considered low-level heterogeneity, 25--50% moderate-level heterogeneity, and 50% high-level heterogeneity) \[[@CR11]\]. Data were pooled based on the random-effect model in the presence of heterogeneity, \[[@CR12]\] otherwise, the fixed-effect model was applied \[[@CR13]\]. In addition, stratified analyses were conducted based on tumor types; sensitivity analysis, Begg's funnel plot and Egger's test \[[@CR14]\] were employed to explore the impact of each research on the overall result and potential publication bias respectively. All *P* values were two-sided and below 0.05 was treated as statistical significance.

Results {#Sec9}
=======

Search results and description of studies {#Sec10}
-----------------------------------------

Flow chart diagram of research selection was displayed in Fig. S[1](#MOESM1){ref-type="media"}. Twenty six researches with 6384 patients were ultimately included in this meta-analysis \[[@CR15]--[@CR40]\]. And all the researches were scored 6 or above after careful evaluation with the Newcastle--Ottawa Scale (NOS); Characteristics of those researches being in the light of the inclusion criteria and suitable for data incorporation were exhibited in Table [1](#Tab1){ref-type="table"} and Table S[1](#MOESM1){ref-type="media"}. Table 1Main characteristics of the included studiesStudyYearTumor typeNo. of PatientsMale/Femalemedian age (range) (year)StainingTATE: Present / absentTumor stagemedian follow-up date (months)SurvivalQuality Score (NOS)Peurala, E. etal \[[@CR15]\]2018Oral cancer9955/4465.3H&E51/47I - III40.7OS8Oliveira, D. T. etal \[[@CR16]\]2012Oral cancer7155/1659 (35, 77)H&E35/36I - IINRDFS7Tostes Oliveira, D. etal \[[@CR19]\]2009Oral cancer4327/1655.79 (28, 83)H&E21/22I - IV(3, 229)OS7Dorta, R. G. etal \[[@CR17]\]2002Oral cancer125105/2058 (30, 95)H&E57/68II - III88.2 (0, 287.4)OS, DFS7Dante, P. etal \[[@CR40]\]2019Tongue Carcinoma259223/3653.0 ± 12.2H&ENRI - IVNROS, DFS8Alrawi, S. J. etal \[[@CR18]\]2005Head and neck carcinoma87NR(41, 76)H&E13/7II - IV36 (6, 216)OS, DFS7Ercan, I. etal \[[@CR20]\]2005Laryngeal carcinoma7878/055.9 (35, 80)H&E25/53NR41.91OS7Sassler, A. M. etal \[[@CR21]\]1995Laryngeal carcinoma248NRNRH&E56/192III - IV48OS, DFS6Thompson, A. C. etal \[[@CR22]\]1994Laryngeal carcinoma10485/1964.6 (39, 91)H&E31/73NR≥ 60OS6Fujii, M. etal \[[@CR23]\]2002Nasopharyngeal carcinoma5340/1349.4 (15, 81)H&E26/27I - IV90.5 (35.3, 199.9)DFS7Leighton, S. E. etal \[[@CR24]\]1996Nasopharyngeal carcinoma9668/28NRH&E65/31NR57OS, DFS6Harbaum, L. etal \[[@CR25]\]2015Colorectal cancer381166/21568.5H&E101/280I - IV45 (1, 182)OS8Fernandez-Acenero, M. J. etal \[[@CR26]\]2000Colorectal cancer12670/5667.35 (32, 87)H&E29/97Duke's A-C≥ 60OS, DFS8Nielsen, H.J. etal \[[@CR27]\]1999Colorectal cancer584240/34461 (49, 75)H&E150/115Duke's A-D61 (49, 75)OS7Prizment, A. E etal \[[@CR28]\]2016Colorectal cancer4410/441(55, 69)H&E; EPX197 /244NR60OS8Zhang, Y. etal \[[@CR29]\]2014Esophageal carcinoma3625/1159 (45, 77)H&E18/18I - IV22 (2, 143)OS7Ishibashi, S. etal \[[@CR30]\]2006Esophageal carcinoma9782/1562.7 ± 8.9H&E30/31NR61.7 (5.3, 165.4)OS7Hollander, P. etal \[[@CR31]\]2018Hodgkin's lymphoma459242/217\< 45: 68%; ≥45: 32%H&ENRI - IV154.8OS8Kereszres, K. etal \[[@CR32]\]2007Hodgkin's lymphoma10454/5033 (12, 72)H&E64/40I - IV110 (24, 214)OS, DFS7von Wasielewski, R. etal \[[@CR33]\]2000Hodgkin's lymphoma1511745/766(15, 75)H&E510/823I - IV120OS8Enblad, G.etal \[[@CR34]\]1993Hodgkin's lymphoma140NR45 (11, 94)H&E26/114I - IV48 (20, 85)DFS6van Driel, W.J. etal \[[@CR35]\]1996Cervical cancer830/8342.1H&ENRI - IIA44.6 (5, 108)OS, DFS7Bethwaite, P. B. etal \[[@CR36]\]1993Cervical cancer670/6743.7 (25, 76)H&E28/39IB62.4 (1, 93)OS7Flamm, J. etal \[[@CR37]\]1992Bladder cancer428289/13970.2 (29, 91)H&E99/329NR84OS7Iwasaki, K. etal \[[@CR38]\]1986Gastric cancer647364/283(22, 84)H&E157/490I - IV(8, 92)OS7Ono, Y. etal \[[@CR39]\]2002Penile cancer1717/068 (36, 84)H&E9/8I - IVNROS6*H&E* haematoxilyn and eosin, *EPX* eosinophil peroxide, *NR *not reported

Meta-analyses {#Sec11}
-------------

### Overall survival (OS) {#Sec12}

In this meta-analysis, we discovered that the presence of TATE was notably associated with improved OS (HR = 0.82, 95% CI 0.68 to 0.99, *P* = 0.041) in patients with solid tumor. (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Forest plots describing HR of the association between TATE and OS in human solid tumors

In stratified analyses according to tumor types, the combined results manifested that TATE was markedly associated with better OS in colorectal cancer (CRC) (HR = 0.70, 95% CI 0.58 to 0.84, *P* = 0.000), with no heterogeneity detected (*I*^*2*^ *= 0%, P = 0.449)*. Similar data was obtained between TATE and OS in esophageal carcinoma (EC) (HR = 0.35, 95% CI 0.14 to 0.88, *P* = 0.026); Whereas no distinct relation existed between eosinophil infiltration and OS in oral cancer (OC) (HR = 0.89, 95% CI 0.53 to 1.49, *P* = 0.657), laryngeal carcinoma (HR = 0.87, 95% CI 0.51 to 1.48, *P* = 0.599), Hodgkin's lymphoma (HR = 0.90, 95% CI 0.48 to 1.69, *P* = 0.741) or cervical cancer (HR = 2.14, 95% CI 0.38 to 12.24, *P* = 0.391). (Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Stratified analyses describing HRs of the association between TATE and OS

### Disease-free survival (DFS) {#Sec13}

As for DFS, the meta-analysis indicated that no noticeable association existed between eosinophil infiltration and DFS (HR = 1.13, 95% CI 0.72 to 1.77, *P* = 0.598) in solid tumors. (Fig. [3](#Fig3){ref-type="fig"}) In the stratified analyses, the incorporated results revealed that TATE was not significantly associated with improved DFS in oral cancer (HR = 1.83, 95% CI 0.65 to 5.15, *P* = 0.253), nasopharyngeal carcinoma (HR = 0,50, 95% CI 0.23 to 1.08, *P* = 0.079) or Hodgkin's lymphoma (HR = 0.73, 95% CI 0.18 to 2.98, *P* = 0.657). (Fig. [4](#Fig4){ref-type="fig"}). Fig. 3Forest plots describing HR of the association between TATE and DFS in human solid tumorsFig. 4Stratified analyses describing HRs of the association between eosinophil infiltration and DFS

### Clinicopathological features {#Sec14}

We next tested the relation between TATE and clinicopathological features, and found that TATE was remarkably inversely correlated with lymph node metastasis (OR = 0.59, 95% CI 0.40 to 0.87, *P* = 0.007), TNM stage (OR = 1.70, 95% CI 1.12 to 2.58, *P* = 0.013) and lymphatic invasion (OR = 0.58, 95% CI 0.36 to 0.91, *P* = 0.018), but not with vascular invasion (OR = 0.79, 95% CI 0.50 to 1.25, *P* = 0.308) of patients. (Fig. [5](#Fig5){ref-type="fig"}). Fig. 5Forest plots indicating ORs of the association between eosinophil infiltration and clinicopathological feature

### Sensitivity analysis {#Sec15}

Sensitivity analysis demonstrated that each included research had no impact on the overall result for OS or DFS. (Fig. S[2](#MOESM1){ref-type="media"}).

### Publication bias {#Sec16}

No publication bias existed between TATE and OS (*P* = 0.152) or DFS (*P* = 0.876) in patients by Funnel plot (Fig. S[3](#MOESM1){ref-type="media"}) and Egger's test.

Discussion {#Sec17}
==========

Eosinophilia is commonly associated with allergies, helminth infections and several inflammatory states. Recently, it has also been noted in human solid tumors. The present meta-analysis revealed that TATE had a positive effect in improving survival in human solid tumors, especially in CRC and EC. Moreover, It significantly inversely correlated with lymph node metastasis etc. of tumor. Hence, these data offered important evidence in uncovering the positive prognostic role of TATE in human solid tumors.

The close relation between TATE and better clinical outcome identified in this study possibly attribute to the following reasons: eosinophils in the TME can express same receptors and mediators such as granzyme A etc. as cytotoxic T lymphocytes (CTLs) and be directly involved in anti-tumor response, \[[@CR41]\] and they can also secret several chemokines including CCL5, CXCL9 to promote anti-tumor immunity through attracting CD8^+^ T cells to the tumor site \[[@CR42]\]. In addition, eosinophils are capable of regulating immunity, for instance, they can release major basic protein (MBP), a highly cationic protein to stimulate maturation of dendritic cells by increasing cell surface activation markers including MHC-II, CD80 and CD86, \[[@CR43]\] which has the potential to overcome immune tolerance and induce anti-tumor immunity with the powerful antigen-presentation ability \[[@CR44]\]. Furthermore, they can induce cell death of various cell lines such as colo-205 cell line with some selectivity in their tumoricidal properties, which are dependent on the CD11a/CD18-mediated stable contacts with target cells \[[@CR45]\]. Hence, it is rational to conclude that TATE is capable of regulating tissue homeostasis of the TME and inhibiting tumor growth and metastasis thereby improving survival. However, in other tumor types, TATE as a prognostic marker for survival has been a controversial issue. This may be because of differences in methods of counting TATE as well as heterogeneity of material.

Previous studies have demonstrated that cytokines such as IL-2, IL-4 could recruit eosinophils and lead to eosinophilia and enhanced eosinophil activation, thereby exert potent anti-tumor immune responses \[[@CR41], [@CR46]\]. Thus, based on our present result that TATE improving survival in human solid tumors identified in this study and the function of IL-2 and IL-4 stated above, we harbor the idea that clinical application of biological response modifiers (BRM) such as carrier-assisted recombined human IL-2 /or IL-4 may have the potential to treat human solid tumors.

Quite a few limitations should be noted from this study. First, morphometric analyses for TATE adopted in included researches were not exactly consistent. In addition, researches with negative results might not be published, which might result in potential publication bias.

Conclusions {#Sec18}
===========

TATE promotes survival in solid tumors especially in CRC and EC, suggesting that it is a valuable prognostic biomarker and clinical application of biological response modifiers or agonists promoting TATE may be a novel therapeutic strategy for patients.

Supplementary information
=========================

 {#Sec19}

**Additional file 1: Figure S1.** Flow chart diagram of study selection. **Figure S2.** Plots describing the influence of individual studies on the overall HRs for OS (**A**) and DFS (**B**) in human cancers. **Figure S3.** Funnel plots displayed the potential publication bias between TATE and OS (**A**) or DFS (**B**) in patients. **Table S1.** Characteristics of the included studies for OR analysis of clinicopathological features.
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